NCT07270419 Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program
| NCT ID | NCT07270419 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xiaolin Chen, MD |
| Condition | Aneurysmal Subarachnoid Hemorrhage |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2023-11-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening cerebrovascular emergency with high mortality and disability rates. Despite advances in neuroimaging and interventional techniques, outcomes remain poor for many patients due to complex post-rupture complications such as delayed cerebral ischemia (DCI), pneumonia, and other systemic injuries. These secondary events critically affect neurological recovery, yet their molecular mechanisms are not fully understood. This multicenter study aims to investigate the biological basis of post-rupture complications and prognosis in patients with aSAH through integrated multi-omics and clinical data analysis. Biospecimens including blood, cerebrospinal fluid, urine, and other relevant tissues will be collected for genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling. By linking molecular data with clinical and imaging indicators, the study seeks to identify key pathways and biomarkers associated with secondary injury and outcome heterogeneity.
Eligibility Criteria
Inclusion Criteria: 1. Adult patients aged ≥18 years; 2. Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH) by CTA, or DSA; 3. Aneurysm secured by either microsurgical clipping or endovascular coiling during hospitalization; 4. Time from onset to aneurysm treatment ≤ 72 hours; 5. Availability of biospecimens, including blood, cerebrospinal fluid (CSF), urine, or fecal samples collected during hospitalization; 6. Signed informed consent obtained from the patient or legal representative. Exclusion Criteria: 1. History of previous intracranial aneurysm surgery or embolization; 2. Non-aneurysmal SAH, traumatic SAH, or perimesencephalic non-aneurysmal hemorrhage; 3. Presence of malignancy, severe hepatic or renal dysfunction, or other systemic diseases that may affect survival or biomarker expression; 4. Severe cardiorespiratory insufficiency or unstable medical condition precluding study participation; 5. Pregnancy or lactation; 6. Refusal to participate or withdrawal of consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07270419 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Aneurysmal Subarachnoid Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07270419 currently recruiting?
Yes, NCT07270419 is actively recruiting participants. Contact the research team at tt18080lrt@163.com for enrollment information.
Where is the NCT07270419 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07270419 clinical trial?
NCT07270419 is sponsored by Xiaolin Chen, MD. The trial plans to enroll 2,000 participants.